Cornerstone Wealth Group LLC Purchases 4,405 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cornerstone Wealth Group LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 114.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,270 shares of the biopharmaceutical company's stock after purchasing an additional 4,405 shares during the period. Cornerstone Wealth Group LLC's holdings in Regeneron Pharmaceuticals were worth $5,245,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. Pinney & Scofield Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $25,000. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares in the last quarter. OFI Invest Asset Management bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $28,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares in the last quarter. Finally, Avalon Trust Co acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $36,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 0.4%

Shares of REGN traded down $1.98 during mid-day trading on Wednesday, hitting $520.29. 639,462 shares of the company's stock were exchanged, compared to its average volume of 891,375. The stock has a market cap of $56.17 billion, a price-to-earnings ratio of 13.25, a P/E/G ratio of 1.87 and a beta of 0.31. The firm has a fifty day moving average of $556.44 and a two-hundred day moving average of $637.35. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same period in the previous year, the company earned $9.55 earnings per share. The company's quarterly revenue was down 3.7% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on REGN. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Morgan Stanley cut their price objective on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating on the stock in a report on Monday, June 2nd. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a report on Monday, June 9th. Royal Bank Of Canada lowered shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price target on the stock. in a report on Friday, May 30th. Finally, Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $836.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.